3-Phenyl-6-(3,4-dimethylphenylamino)uracil | 90995-13-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-Phenyl-6-(3,4-dimethylphenylamino)uracil
• 英文别名: 6-(3,4-dimethylanilino)-3-phenyl-1H-pyrimidine-2,4-dione
• CAS: 90995-13-4
• 化学式: C₁₈H₁₇N₃O₂
• 分子量: 307.352
• InChiKey: MRMINDOZLMRNLM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  61.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-Phenyl-6-(3,4-dimethylphenylamino)uracil 、 2-Hydroxymethylen-cholest-4-en-3-on 在 对甲苯磺酸 作用下， 以 二苯醚 为溶剂， 反应 0.75h， 以44%的产率得到(1R,3aS,3bS,13aR,13bS,15aR)-7-(3,4-dimethylphenyl)-13a,15a-dimethyl-1-((R)-6-methylheptan-2-yl)-10-phenyl-1,2,3,3a,3b,4,5,7,13,13a,13b,14,15,15a-tetradecahydro-9H-cyclopenta[5,6]naphtho[1,2-g]pyrimido[4,5-b]quinoline-9,11(10H)-dione
  参考文献：
  名称：

  Synthesis, biological active molecular design, and molecular docking study of novel deazaflavin–cholestane hybrid compounds

  摘要：

  Novel deazaflavin-cholestane hybrid compounds, 3',8'-disubstituted-5'-deazacholest-2,4-dieno[2,3g] pteridine-2',4'(3'H, 8'H)-diones, have been synthesized by condensation reaction between 6-(monosubstituted amino)-pyrimidin-2,4(1H,3H)-diones and 2-hydroxymethylenecholest-4-en-3-one in presence of p-toluenesulfonic acid monohydrate and diphenyl ether. The antitumor activities against human tumor cell lines (CCRF-HSB-2 and KB cells) have been investigated in vitro, and many of these compounds showed promising antitumor activities. Furthermore, molecular docking study using LigandFit within the software package Discovery Studio 1.7 was done for lead optimization of these compounds as potential PTK inhibitors. In general, all of the synthesized steroid-hybrid compounds showed good binding affinities into PTK (PDB code: 1t46). (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.07.089
• 作为产物：
  描述：

  3,4-二甲基苯胺 、 6-chloro-3-phenylpyrimidine-2,4(1H,3H)-dione 反应 0.17h， 以81%的产率得到3-Phenyl-6-(3,4-dimethylphenylamino)uracil
  参考文献：
  名称：

  Nagamatsu, Tomohisa; Yamato, Hirotake; Ono, Masami, Journal of the Chemical Society. Perkin transactions I, 1992, # 16, p. 2101 - 2110

  摘要：

  DOI：

文献信息

• Nagamatsu, Tomohisa; Yamato, Hirotake; Ono, Masami, Journal of the Chemical Society. Perkin transactions I, 1992, # 16, p. 2101 - 2110
  作者：Nagamatsu, Tomohisa、Yamato, Hirotake、Ono, Masami、Takarada, Shigeki、Yoneda, Fumio

  DOI：——

  日期：——
• Nagamatsu, Tomohisa; Hashiguchi, Yuko; Yoneda, Fumio, Journal of the Chemical Society. Perkin transactions I, 1984, # 3, p. 561 - 565
  作者：Nagamatsu, Tomohisa、Hashiguchi, Yuko、Yoneda, Fumio

  DOI：——

  日期：——
• NAGAMATSU, TOMOHISA;HASHIGUCHI, YUKO;YONEDA, FUMIO, J. CHEM. SOC. PERKIN TRANS., 1984, N 3, 561-565
  作者：NAGAMATSU, TOMOHISA、HASHIGUCHI, YUKO、YONEDA, FUMIO

  DOI：——

  日期：——
• Synthesis, biological active molecular design, and molecular docking study of novel deazaflavin–cholestane hybrid compounds
  作者：Ajaya R. Shrestha、Takashi Shindo、Noriyuki Ashida、Tomohisa Nagamatsu

  DOI：10.1016/j.bmc.2008.07.089

  日期：2008.9

  Novel deazaflavin-cholestane hybrid compounds, 3',8'-disubstituted-5'-deazacholest-2,4-dieno[2,3g] pteridine-2',4'(3'H, 8'H)-diones, have been synthesized by condensation reaction between 6-(monosubstituted amino)-pyrimidin-2,4(1H,3H)-diones and 2-hydroxymethylenecholest-4-en-3-one in presence of p-toluenesulfonic acid monohydrate and diphenyl ether. The antitumor activities against human tumor cell lines (CCRF-HSB-2 and KB cells) have been investigated in vitro, and many of these compounds showed promising antitumor activities. Furthermore, molecular docking study using LigandFit within the software package Discovery Studio 1.7 was done for lead optimization of these compounds as potential PTK inhibitors. In general, all of the synthesized steroid-hybrid compounds showed good binding affinities into PTK (PDB code: 1t46). (C) 2008 Elsevier Ltd. All rights reserved.